Natco Pharma Ltd. — Interim / Quarterly Report 2019

Feb 12, 2019

==> picture [416 x 43] intentionally omitted <==

February 12, 2019

Corporate Relationship Department Manager – Listing The BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 . Bandra (E) Mumbai 400 051 .

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir,

Sub:- Outcome of Board Meeting

Further to our intimation dated 2[nd] February, 2019, we would like to inform you that the Board of Directors of the Company at their meeting held today have considered the following along with other items of business:

1. Approved Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31[st] December, 2018 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Review Report of the Statutory Auditors. Please find enclosed a copy of the same for your information.

2. Declared second interim dividend of Rs.3.50 ps. (Rupees three and paise fifty only) on each equity share of face value Rs.2/- (Rupees two only) each for the financial year 2018-2019. The date for taking on record of the its shareholders of the company eligible for the purpose of payment of second interim dividend i.e. Record Date is fixed as Friday, the 22[nd] day of February, 2019 . The said interim dividend will be paid from Tuesday, the 26[th] day of February, 2019.

We are also updating the financial results on the website of the Company www.natcopharma.co.in.

A copy of the Press Release also enclosed for your information

This is for your information and records.

Thanking you,

Yours faithfully,

For NATCO Pharma Limited

==> picture [107 x 23] intentionally omitted <==

M Adinarayana Company Secretary & Vice President (Legal & Corp. Affairs)

Encl: as above

==> picture [450 x 47] intentionally omitted <==

Ref:PR/12/2019 Hyderabad, 12[th] February, 2019

Press Release

NATCO records INR 580.0 Crore revenue and INR 159.3 Crore of Profit, after tax, for the Third Quarter, FY 2018-19

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenues of INR 580.0 Crore for the quarter ended on 31[st] December, 2018, as against INR 573.6 Crore during the same quarter last year.

The net profit for the period, on a consolidated basis, was INR 159.3 Crore, as against INR 217.4 Crore same quarter last year. The decline in profits during the quarter compared to last year was predominantly due to margin reduction of Oseltamivir in the USA market.

Revenue Split (approx.) for Quarter 3, FY2019-

e Split (approx.) for Quarter 3, FY2019-
API	-	INR 99 Cr
Formulations, Domestic	-	INR 164 Cr
Formulations, Exports (incl Profit Share)	-	INR 257 Cr
Foreign Subsidiaries	-	INR 25 Cr
Other Operating & Other Income	-	INR 35 Cr

The Board of Directors has recommended an interim dividend of INR 3.50 per equity share of INR 2/-each.

---

Forwarded for favour of publication

For NATCO Pharma Limited

==> picture [106 x 23] intentionally omitted <==

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs